Our client is an ophthalmology focused company that is motivated to improve the treatment burden of patients with retinal diseases (Glaucoma, etc.) via a novel VEGF-independent drug delivery platform. This drug will last up to six months versus six weeks through the current drug delivery method. They are currently seeking an experienced CEO to join their team. This position can sit remote (virtual) anywhere in the US.
May 21, 2021